Spots Global Cancer Trial Database for hematologic malignancy
Every month we try and update this database with for hematologic malignancy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome | NCT05413356 | Bronchiolitis O... Hematologic Mal... | Ruxolitinib | 18 Years - 65 Years | First Affiliated Hospital of Zhejiang University | |
| Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies | NCT05707325 | Cancer Solid Tumor Hematologic Mal... | engineered red ... | 18 Years - 75 Years | Westlake Therapeutics | |
| Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy | NCT02139280 | Hematologic Mal... | Cyclophosphamid... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Distracting Through Procedural Pain and Distress | NCT04892160 | Chronic Illness Hematologic Mal... Bone Marrow Tra... Oncology Sickle Cell Dis... | Guided Imagery Virtual Reality | 8 Years - 25 Years | Medical College of Wisconsin | |
| Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | NCT01846429 | Tumor Cancer Pain Malignant Solid... Unresectable Ma... Hematologic Mal... Multiple Myelom... Lymphoma Neoplasm Metast... | Sodium Bicarbon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies | NCT00840190 | Solid Tumor Hematologic Mal... | P1446A-05 | 18 Years - | Piramal Enterprises Limited | |
| Expressive Helping for Stem Cell Transplant Patients | NCT03800758 | Stem Cell Trans... Hematologic Mal... | Expressive Help... Factual Writing | 18 Years - | Northwestern University | |
| Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation | NCT06102213 | Hematologic Mal... | B. infantis (PB... | 18 Years - 75 Years | Prolacta Bioscience | |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | NCT04156256 | Hematologic Mal... Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Myeloid... | CD123-CD33 cCAR... | - | iCell Gene Therapeutics | |
| Removing Transfusion Dependence as a Barrier to Hospice Enrollment | NCT05063591 | Hematologic Mal... Myelodysplastic... Acute Myeloid L... Lymphoma Leukemia Myeloma | Transfusion sup... | 18 Years - | Brown University | |
| Radiation Post-CAR T in Refractory Lymphoma | NCT04473937 | Hematologic Mal... Refractory Lymp... | Radiotherapy | 18 Years - | Massachusetts General Hospital | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | NCT04395222 | Hematologic Mal... Bone Marrow Tra... | Tocilizumab Fludarabine Melphalan Anti-thymocyte ... Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| Transfusional Iron Overload Among Leukemia Survivors | NCT01965171 | Acute Lymphocyt... Acute Myeloid L... | 5 Years - | St. Jude Children's Research Hospital | ||
| Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation | NCT03680092 | GVHD Hematologic Neo... | Cyclophosphamid... abatacept Methotrexate Tacrolimus | 18 Years - | University of California, San Diego | |
| Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers | NCT02041416 | Cancer Solid Tumor Hematologic Mal... | 65 Years - | City of Hope Medical Center | ||
| Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy | NCT02139280 | Hematologic Mal... | Cyclophosphamid... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | NCT01341301 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Reiki as a Complementary Therapy: A Pilot Study | NCT02207764 | Hematologic Mal... | Reiki | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Immunity to Infection in Healthy Participants and Participants With Cancer | NCT05787964 | Influenza SARS-CoV-2 Hematologic Mal... Solid Tumor | Biological samp... | 18 Years - 90 Years | University Hospital Tuebingen | |
| Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) | NCT00215943 | Multiple Myelom... | zoledronic acid dexamethasone thalidomide vincristine adriamycin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML | NCT05690425 | Hematologic Mal... | BC3402 Injectio... | 18 Years - | Biocity Biopharmaceutics Co., Ltd. | |
| Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies | NCT03717480 | Hematologic Mal... | ClinicMACs | 18 Years - 65 Years | Dana-Farber Cancer Institute | |
| VR for Symptom Control and Wellbeing | NCT04821466 | Oncology End Stage Cance... Palliative Care Hematologic Mal... | Virtual Reality... | 18 Years - | Royal Cornwall Hospitals Trust | |
| Prospective Validation of the OHI Index | NCT05882175 | HLH Hemophagocytic ... Hemophagocytic ... Hematologic Mal... Hematologic Neo... | 18 Years - | Meir Medical Center | ||
| Thrombosomes® in Bleeding Thrombocytopenic Patients Study | NCT04631211 | Thrombocytopeni... Hematologic Mal... Bone Marrow Apl... Myeloproliferat... Myelodysplastic... Platelet Refrac... | Thrombosomes Liquid Stored P... | 18 Years - | Cellphire Therapeutics, Inc. | |
| The Association of Microbiota Composition With cGVHD After Allo-HSCT | NCT05355675 | Hematopoietic S... Hematologic Mal... Chronic Graft-v... Complication | blood sample stool sample | 18 Years - 65 Years | First Affiliated Hospital of Zhejiang University | |
| Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study | NCT00156858 | Hematologic Mal... | intravenous bus... | - 70 Years | AHS Cancer Control Alberta | |
| Oral Complications in Hematological Malignancies | NCT05758207 | Hematologic Mal... | 18 Years - 80 Years | Assiut University | ||
| Using of Virtual Reality to Relieve Procedural Pain in Pediatric Oncology. | NCT05042479 | Hematologic Mal... Hematologic Non... Solid Tumor, Ch... Child, Only | Usual distracti... Virtual reality Choice between ... | 7 Years - 18 Years | Nantes University Hospital | |
| A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011) | NCT01254630 | Herpes Zoster | V212 Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Home Transfusion for HEME | NCT05509439 | Hematologic Mal... | Home Transfusio... | 18 Years - | Dana-Farber Cancer Institute | |
| Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies | NCT03727009 | Hematologic Mal... | Blood Sample Co... | 18 Years - | Exact Sciences Corporation | |
| Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT) | NCT03419078 | Allogeneic Stem... Graft Versus Ho... Hematologic Mal... Stem Cell Trans... | 17 Years - | Imperial College Healthcare NHS Trust | ||
| A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies | NCT06208878 | Hematologic Mal... Solid Malignanc... | Non Interventio... | 18 Years - | CRISPR Therapeutics | |
| Lighting Intervention for Cancer-related Fatigue | NCT04827446 | Breast Cancer Prostate Cancer Hematologic Mal... Survivorship Fatigue | Wearable Sensor Blue-blocking g... Clear glasses Full SYNC app "Dummy" SYNC ap... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | NCT00967343 | Myeloid Leukemi... Lymphoblastic L... Lymphoma Multiple Myelom... Myelodysplastic... Myeloproliferat... | Donor lymphocyt... | 18 Years - 65 Years | Kiadis Pharma | |
| Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation | NCT06102213 | Hematologic Mal... | B. infantis (PB... | 18 Years - 75 Years | Prolacta Bioscience | |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | NCT02743351 | Hematologic Mal... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Acute Graft-ver... | ProTmune Control Arm | 18 Years - | Fate Therapeutics | |
| Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | NCT00133367 | Multiple Myelom... Non-Hodgkin's L... Hodgkin's Disea... Myelogenous Leu... Lymphoblastic L... | Tacrolimus Sirolimus G-CSF Antithymocyte g... Thymoglobulin Fludarabine Melphalan | 18 Years - 65 Years | Massachusetts General Hospital | |
| Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy | NCT05009719 | Hematologic Mal... | Prophylactic Do... Preventive Dono... | 4 Months - 18 Years | St. Petersburg State Pavlov Medical University | |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | NCT06401356 | Hematologic Mal... Solid Tumor Advanced Malign... | Pelabresib | 18 Years - | Constellation Pharmaceuticals | |
| A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies | NCT02352558 | Hematologic Mal... | BBI608 Dexamethasone Bortezomib Imatinib Ibrutinib | 18 Years - | Sumitomo Pharma America, Inc. | |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | NCT00967343 | Myeloid Leukemi... Lymphoblastic L... Lymphoma Multiple Myelom... Myelodysplastic... Myeloproliferat... | Donor lymphocyt... | 18 Years - 65 Years | Kiadis Pharma | |
| Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE) | NCT04392128 | COVID19 Hematologic Mal... | Hydroxychloroqu... Azithromycin 25... Placebo oral ta... Placebo oral ca... | 18 Years - | Institut de cancérologie Strasbourg Europe | |
| Influenza Vaccine Post Allogeneic Transplant | NCT01215981 | Hematopoietic S... Hematologic Mal... | Influenza vacci... Influenza vacci... | 6 Months - | Masonic Cancer Center, University of Minnesota | |
| Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer | NCT01324323 | Hematologic Mal... Malignant Lymph... | Romidepsin Rifampin | 18 Years - | Celgene | |
| Continuation Study of the Oral AKT Inhibitor GSK2110183 | NCT01531894 | Cancer | GSK2110183 (afu... | 18 Years - 80 Years | Novartis | |
| Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation | NCT02696408 | Hematologic Mal... | Laser treatment Placebo | 18 Years - | Institut de Cancérologie de la Loire | |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | NCT05476770 | Hematologic Mal... AML ALL BPDCN MDS Lymphoblastic L... Lymphoma, B-Cel... Lymphoma, T-Cel... Hodgkin Lymphom... Mixed Phenotype... Acute Undiffere... | Tagraxofusp Fludarabine Cytarabine Dexamethasone Vincristine Azacitidine Methotrexate Cytarabine IT Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients | NCT05294380 | Sarcopenia Pediatric Cance... | 2 Years - 18 Years | Trakya University | ||
| Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant | NCT05709912 | Bone Marrow Tra... Hematologic Mal... | CARE Applicatio... Usual Care | 18 Years - | Massachusetts General Hospital | |
| Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor | NCT02500550 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... | ATIR101 Haploidentical ... TBI regime Non-TBI regime | 18 Years - 65 Years | Kiadis Pharma | |
| Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE) | NCT04392128 | COVID19 Hematologic Mal... | Hydroxychloroqu... Azithromycin 25... Placebo oral ta... Placebo oral ca... | 18 Years - | Institut de cancérologie Strasbourg Europe | |
| A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors | NCT06153797 | Hematologic Mal... Caregiver | PATH-C | 18 Years - | Brigham and Women's Hospital | |
| Molecular-genetic Characterization in Patients Undergoing CAR-T Cell Infusion | NCT05807789 | Hematologic Mal... | 18 Years - 70 Years | IRCCS Azienda Ospedaliero-Universitaria di Bologna | ||
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| Effectiveness of High Flow Oxygen Therapy in Patients With Hematologic Malignancy Acute Hypoxemic Respiratory Failure | NCT03133520 | Acute Hypoxemic... Hematologic Mal... | High flow oxyge... | 18 Years - | TC Erciyes University | |
| Nutritional and Physical Exercise Intervention in Older Patients With Malignant Hemopathies | NCT04057443 | Hematologic Mal... Old Age; Debili... | Nutritional sup... Physical exerci... Hematologic Dru... | 70 Years - | L'Hospitalet de Llobregat | |
| Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | NCT05800210 | Acute Lymphobla... Acute Myeloid L... Juvenile Myelom... Myelodysplastic... Chronic Myeloid... Lymphoma, Non-H... Lymphoma, Hodgk... | Miltenyi CliniM... | 6 Months - 39 Years | University of Florida | |
| Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia | NCT02669706 | Hematologic Mal... | Pentamidine | 18 Years - | University of Illinois at Chicago | |
| A Study of DT2216 in Relapsed/Refractory Malignancies | NCT04886622 | Solid Tumor Hematologic Mal... | DT2216 | 18 Years - | Dialectic Therapeutics, Inc | |
| CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT | NCT05943067 | Hematologic Mal... | CD45RA depleted... | 8 Weeks - 65 Years | University Hospital Tuebingen | |
| Lighting Intervention for Cancer-related Fatigue | NCT04827446 | Breast Cancer Prostate Cancer Hematologic Mal... Survivorship Fatigue | Wearable Sensor Blue-blocking g... Clear glasses Full SYNC app "Dummy" SYNC ap... | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia | NCT00001567 | Hairy Cell Leuk... | Roferon-A | - | National Institutes of Health Clinical Center (CC) | |
| A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy | NCT06211751 | Hematologic Mal... | TQB3909 tablets TQB3702 tablets | 18 Years - 80 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06001788 | AML AML With Mutate... Hematologic Mal... KMT2Ar NPM1 Mutation MLL Rearrangeme... Leukemia Acute Myeloid L... Leukemia, Myelo... Leukemia, Myelo... Acute Leukemia Neoplasms by Hi... | Ziftomenib Fludarabine Idarubicin Cytarabine Gilteritinib Granulocyte col... | 18 Years - | Kura Oncology, Inc. | |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | NCT05476770 | Hematologic Mal... AML ALL BPDCN MDS Lymphoblastic L... Lymphoma, B-Cel... Lymphoma, T-Cel... Hodgkin Lymphom... Mixed Phenotype... Acute Undiffere... | Tagraxofusp Fludarabine Cytarabine Dexamethasone Vincristine Azacitidine Methotrexate Cytarabine IT Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| IRAF-ABLATION Study: a Multicenter International Retrospective Cohort of Patients With BTK Inhibitors-related AF Treated by Catheter Ablation | NCT06130709 | BTKi-induced At... Hematologic Mal... Atrial Fibrilla... | Atrial fibrilla... | 18 Years - 99 Years | University Hospital, Caen | |
| Nutritional and Physical Exercise Intervention in Older Patients With Malignant Hemopathies | NCT04057443 | Hematologic Mal... Old Age; Debili... | Nutritional sup... Physical exerci... Hematologic Dru... | 70 Years - | L'Hospitalet de Llobregat | |
| Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation | NCT05417971 | Hematologic Mal... | Fludarabine | 18 Years - | Northside Hospital, Inc. | |
| Non Invasive Optical Imaging of WBC Count | NCT02512666 | Hematologic Mal... | AM4113-N5UT Din... | 18 Years - | Massachusetts General Hospital | |
| Influence of CYP2C19 Genotype on Safety and Efficacy of Voriconazole in Pediatric Patients With Hematologic Malignancy | NCT04743544 | Adverse Drug Re... | Voriconazole | 2 Years - 18 Years | Dokuz Eylul University | |
| Exercise Prehab in Older Adults With Hematologic Malignancies | NCT02791737 | Hematopoietic a... | Exercise Interv... Laboratory Biom... Physical Therap... Quality-of-Life... Questionnaire A... | 60 Years - | Ohio State University Comprehensive Cancer Center | |
| Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | NCT04537715 | All Malignancie... Advanced Malign... Hematologic Mal... Solid Tumor Follicular Lymp... Non-Hodgkin Lym... Diffuse Large B... Epithelioid Sar... Synovial Sarcom... Renal Medullary... Mesothelioma Rhabdoid Tumor | Tazemetostat Itraconazole Tazemetostat Rifampin | 18 Years - | Ipsen | |
| Sexual Health in Patients With Hematologic Malignancies | NCT05222282 | Sexuality Sexual Dysfunct... Psychological Quality of Life Symptoms and Si... | Sexual Health | 18 Years - | Rigshospitalet, Denmark | |
| Symptom Identification and Management in Patients With Hematological Malignancy During Follow-up Care | NCT04757545 | Hematologic Mal... | HM-PRO | 18 Years - | Rigshospitalet, Denmark | |
| Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT | NCT05084027 | Hematologic Mal... Older Patients Allogeneic Hema... | venetoclax comb... | 50 Years - 80 Years | First Affiliated Hospital of Zhejiang University | |
| Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients | NCT05294380 | Sarcopenia Pediatric Cance... | 2 Years - 18 Years | Trakya University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
